Genomics and the impact of new technologies on the management of colorectal cancer

D. Paul Harkin*

*Corresponding author for this work

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

High-throughput genomic technologies have the potential to have a major impact on preclinical and clinical drug development and the selection and stratification of patients in clinical trials. These technologies, which are at varying stages of commercialization, include array-based comparative genomic hybridization, single-nucleotide polymorphism arrays, and (the most mature example) expression-based arrays. One of the rate-limiting steps in the routine clinical application of expression array-based technology is the need for suitable clinical samples. One of the major challenges moving forward, therefore, relates to the ability to use formalin-fixed, paraffin-embedded--derived tissue in expression profiling-based approaches.
Original languageEnglish
Pages (from-to)988-991
Number of pages4
JournalThe Oncologist
Volume11
Issue number9
DOIs
Publication statusPublished - Oct 2006

Fingerprint

Genomics
Colorectal Neoplasms
Technology
Comparative Genomic Hybridization
Paraffin
Patient Selection
Formaldehyde
Single Nucleotide Polymorphism
Clinical Trials
Pharmaceutical Preparations

Keywords

  • Array-based comparative genomic hybridization
  • Formalin-fixed paraffin-embedded
  • Genomics
  • Microarrays
  • RNA later
  • Single-nucleotide polymorphism arrays

Cite this

@article{ecb15455c34d4fccb812ed37a8eead3b,
title = "Genomics and the impact of new technologies on the management of colorectal cancer",
abstract = "High-throughput genomic technologies have the potential to have a major impact on preclinical and clinical drug development and the selection and stratification of patients in clinical trials. These technologies, which are at varying stages of commercialization, include array-based comparative genomic hybridization, single-nucleotide polymorphism arrays, and (the most mature example) expression-based arrays. One of the rate-limiting steps in the routine clinical application of expression array-based technology is the need for suitable clinical samples. One of the major challenges moving forward, therefore, relates to the ability to use formalin-fixed, paraffin-embedded--derived tissue in expression profiling-based approaches.",
keywords = "Array-based comparative genomic hybridization, Formalin-fixed paraffin-embedded, Genomics, Microarrays, RNA later, Single-nucleotide polymorphism arrays",
author = "Harkin, {D. Paul}",
year = "2006",
month = "10",
doi = "10.1634/theoncologist.11-9-988",
language = "English",
volume = "11",
pages = "988--991",
journal = "The Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "9",

}

Genomics and the impact of new technologies on the management of colorectal cancer. / Harkin, D. Paul.

In: The Oncologist, Vol. 11, No. 9, 10.2006, p. 988-991.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Genomics and the impact of new technologies on the management of colorectal cancer

AU - Harkin, D. Paul

PY - 2006/10

Y1 - 2006/10

N2 - High-throughput genomic technologies have the potential to have a major impact on preclinical and clinical drug development and the selection and stratification of patients in clinical trials. These technologies, which are at varying stages of commercialization, include array-based comparative genomic hybridization, single-nucleotide polymorphism arrays, and (the most mature example) expression-based arrays. One of the rate-limiting steps in the routine clinical application of expression array-based technology is the need for suitable clinical samples. One of the major challenges moving forward, therefore, relates to the ability to use formalin-fixed, paraffin-embedded--derived tissue in expression profiling-based approaches.

AB - High-throughput genomic technologies have the potential to have a major impact on preclinical and clinical drug development and the selection and stratification of patients in clinical trials. These technologies, which are at varying stages of commercialization, include array-based comparative genomic hybridization, single-nucleotide polymorphism arrays, and (the most mature example) expression-based arrays. One of the rate-limiting steps in the routine clinical application of expression array-based technology is the need for suitable clinical samples. One of the major challenges moving forward, therefore, relates to the ability to use formalin-fixed, paraffin-embedded--derived tissue in expression profiling-based approaches.

KW - Array-based comparative genomic hybridization

KW - Formalin-fixed paraffin-embedded

KW - Genomics

KW - Microarrays

KW - RNA later

KW - Single-nucleotide polymorphism arrays

UR - http://www.scopus.com/inward/record.url?scp=33749864510&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.11-9-988

DO - 10.1634/theoncologist.11-9-988

M3 - Article

C2 - 17030639

VL - 11

SP - 988

EP - 991

JO - The Oncologist

JF - The Oncologist

SN - 1083-7159

IS - 9

ER -